Post COVID-19 irritable bowel syndrome.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Marasco Giovanni, Cremon Cesare, Barbaro Maria Raffaella, Cacciari Giulia, Falangone Francesca, Kagramanova Anna, Bordin Dmitry, Drug Vasile, Miftode Egidia, Fusaroli Pietro, Mohamed Salem Youssef, Ricci Chiara, Bellini Massimo, Rahman Mohammed Masudur, Melcarne Luigi, Santos Javier, Lobo Beatriz, Bor Serhat, Yapali Suna, Akyol Deniz, Sapmaz Ferdane Pirincci, Urun Yonca Yilmaz, Eskazan Tugce, Celebi Altay, Kacmaz Huseyin, Ebik Berat, Binicier Hatice Cilem, Bugdayci Mehmet Sait, Yağcı Munkhtsetseg Banzragch, Pullukcu Husnu, Kaya Berrin Yalınbas, Tureyen Ali, Hatemi İbrahim, Koc Elif Sitre, Sirin Goktug, Calıskan Ali Riza, Bengi Goksel, Alıs Esra Ergun, Lukic Snezana, Trajkovska Meri, Hod Keren, Dumitrascu Dan, Pietrangelo Antonello, Corradini Elena, Simren Magnus, Sjölund Jessica, Tornkvist Navkiran, Ghoshal Uday C, Kolokolnikova Olga, Colecchia Antonio, Serra Jordi, Maconi Giovanni, De Giorgio Roberto, Danese Silvio, Portincasa Piero, Di Sabatino Antonio, Maggio Marcello, Philippou Elena, Lee Yeong Yeh, Salvi Daniele, Venturi Alessandro, Borghi Claudio, Zoli Marco, Gionchetti Paolo, Viale Pierluigi, Stanghellini Vincenzo, Barbara Giovanni, GI-COVID19 study group
Аннотация
DESIGN: GI-COVID-19 is a prospective, multicentre, controlled study. Patients with and without COVID-19 diagnosis were evaluated on hospital admission and after 1, 6 and 12 months post hospitalisation. Gastrointestinal symptoms, anxiety and depression were assessed using validated questionnaires.
RESULTS: The study included 2183 hospitalised patients. The primary analysis included a total of 883 patients (614 patients with COVID-19 and 269 controls) due to the exclusion of patients with pre-existing gastrointestinal symptoms and/or surgery. At enrolment, gastrointestinal symptoms were more frequent among patients with COVID-19 than in the control group (59.3% vs 39.7%, p<0.001). At the 12-month follow-up, constipation and hard stools were significantly more prevalent in controls than in patients with COVID-19 (16% vs 9.6%, p=0.019 and 17.7% vs 10.9%, p=0.011, respectively). Compared with controls, patients with COVID-19 reported higher rates of irritable bowel syndrome (IBS) according to Rome IV criteria: 0.5% versus 3.2%, p=0.045. Factors significantly associated with IBS diagnosis included history of allergies, chronic intake of proton pump inhibitors and presence of dyspnoea. At the 6-month follow-up, the rate of patients with COVID-19 fulfilling the criteria for depression was higher than among controls.
CONCLUSION: Compared with controls, hospitalised patients with COVID-19 had fewer problems of constipation and hard stools at 12 months after acute infection. Patients with COVID-19 had significantly higher rates of IBS than controls.
TRIAL REGISTRATION NUMBER: NCT04691895.